Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 8 of 17 for:    Wet Age-related Macular Degeneration | Pensacola, Florida, U.S.

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections (MERLIN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03710564
Recruitment Status : Recruiting
First Posted : October 18, 2018
Last Update Posted : July 12, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to compare safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those nAMD patients with retinal fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Condition or disease Intervention/treatment Phase
Age-Related Macular Degeneration Biological: Brolucizumab Biological: Aflibercept Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: multicenter, randomized, double-masked
Masking: Double (Participant, Investigator)
Masking Description: Additionally, the care provider will be masked.
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)
Actual Study Start Date : October 30, 2018
Estimated Primary Completion Date : June 9, 2020
Estimated Study Completion Date : September 29, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Masked Arm 1
Brolucizumab 6 mg dosed every 4 weeks from Baseline (Week 0) through Week 48
Biological: Brolucizumab
6 mg/0.05mL solution for intravitreal injection
Other Name: RTH258

Active Comparator: Masked Arm 2
Aflibercept 2 mg dosed every 4 weeks from Baseline (Week 0) through Week 48
Biological: Aflibercept
2 mg/0.05mL solution for intravitreal injection
Other Name: EYLEA




Primary Outcome Measures :
  1. Change from baseline in Best-Corrected Visual Acuity (BCVA) at Week 52 [ Time Frame: Baseline (Week 0), Week 52 ]
    BCVA will be assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing protocol at an initial testing distance of 4 meters. Baseline BCVA is defined as the last measurement on or prior to the baseline visit.


Secondary Outcome Measures :
  1. Stable VA or improvement in VA at Week 52 [ Time Frame: Baseline, Week 52 ]
    BCVA will be assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing protocol at an initial testing distance of 4 meters. The number of subjects with no change or gain in BCVA compared to baseline will be reported.

  2. Loss in BCVA of 5/10/15 letters or more from baseline to each post-baseline visit [ Time Frame: Baseline, Up to Week 52 ]
    BCVA will be assessed using the ETDRS visual acuity testing protocol at an initial testing distance of 4 meters. The number of subjects with loss in BCVA of 5/10/15 letters or more from baseline will be reported for each post-baseline visit.

  3. Gain in BCVA of 5/10/15 letters or more from baseline to each post-baseline visit [ Time Frame: Baseline, Up to Week 52 ]
    BCVA will be assessed using the ETDRS visual acuity testing protocol at an initial testing distance of 4 meters. The number of subjects with gain in BCVA of 5/10/15 letters or more from baseline will be reported for each post-baseline visit.

  4. Change in Central Subfield Thickness (CST) from baseline to each post-baseline visit [ Time Frame: Baseline, Up to Week 52 ]
    CST will be assessed using Spectral Domain Optical Coherence Tomography (SD-OCT) images.

  5. Intraretinal fluid (IRF) at each post-baseline visit [ Time Frame: Up to Week 52 ]
    IRF will be assessed using SD-OCT images. The number of subjects with IRF (present, absent) will be reported for each post-baseline visit.

  6. Subretinal fluid (SRF) at each post-baseline visit [ Time Frame: Up to Week 52 ]
    SRF will be assessed using SD-OCT images. The number of subjects with SRF (present, absent) will be reported for each post-baseline visit.

  7. Sub-Retinal Pigment Epithelium (sub-RPE) fluid in patients with sub-RPE fluid at baseline [ Time Frame: Baseline, Up to Week 52 ]
    Sub-RPE fluid will be assessed using SD-OCT images. The number of subjects with sub-RPE fluid in subjects with sub-RPE fluid at baseline (present, absent) will be reported for each post-baseline visit.

  8. Fluid-free status (no IRF, SRF or sub-RPE fluid) at each post-baseline treatment visit [ Time Frame: Up to Week 52 ]
    IRF, SRF, and sub-RPE fluid will assessed using SD-OCT images. The number of subjects with fluid-free status (no IRF, SRF, or sub-RPE) will be reported for each post-baseline visit.

  9. Time to first dry retina (no IRF or SRF) finding [ Time Frame: Time to event (Baseline, Up to Week 52) ]
    IRF and SRF will be assessed using SD-OCT images. A dry retina is defined as no IRF or SRF at the visit.

  10. Time to first sustained dry retina (no IRF or SRF at ≥ 2 consecutive visits) finding [ Time Frame: Time to event (Baseline, Up to Week 52) ]
    IRF and SRF will be assessed using SD-OCT images. A sustained dry retina is defined as no IRF or SRF at 2 or more consecutive visits.

  11. Change in anti-drug antibody (ADA) levels from baseline [ Time Frame: Baseline, Up to Week 52 ]
    A blood sample will be collected. The baseline sample will be collected prior to first dose of study treatment. This outcome measure is pre-specified for the brolucizumab arm only.

  12. Change in systemic brolucizumab levels from baseline [ Time Frame: Baseline, Up to Week 52 ]
    A blood sample will be collected. The baseline sample will be collected prior to first dose of study treatment. This outcome measure is pre-specified for the brolucizumab arm only.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Sign informed consent
  • Diagnosis of wet age-related macular degeneration (AMD)
  • Currently receiving anti-VEGF injections

Exclusion Criteria:

  • Active infection or inflammation in either eye
  • Significant fibrosis in the study eye
  • Recent ocular surgery
  • Uncontrolled glaucoma
  • Previous treatment with brolucizumab in the study eye
  • Use of medications as specified in the protocol
  • Pregnant, nursing
  • Of child-bearing potential unless using highly effective method of contraception

Other protocol-defined inclusion/exclusion criteria may apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03710564


Contacts
Layout table for location contacts
Contact: Novartis Pharmaceuticals 1-888-669-6682 novartis.email@novartis.com
Contact: Novartis Pharmaceuticals

  Show 62 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03710564     History of Changes
Other Study ID Numbers: CRTH258AUS04
First Posted: October 18, 2018    Key Record Dates
Last Update Posted: July 12, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
neovascular age-related macular degeneration
nAMD
intravitreal injection
IVT
anti-VEGF
brolucizumab
aflibercept
EYLEA
double-masked
MERLIN

Additional relevant MeSH terms:
Layout table for MeSH terms
Macular Degeneration
Wet Macular Degeneration
Retinal Degeneration
Retinal Diseases
Eye Diseases